Free Trial

Venus Concept Q3 2023 Earnings Report

Venus Concept logo
$2.39 +0.13 (+5.75%)
As of 04/3/2025 04:00 PM Eastern

Venus Concept EPS Results

Actual EPS
-$18.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Venus Concept Revenue Results

Actual Revenue
$17.62 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Venus Concept Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Remove Ads

Venus Concept Earnings Headlines

Venus Concept announces $11M debt-to-equity exchange transaction
Short Interest in Venus Concept Inc. (NASDAQ:VERO) Increases By 32.8%
EU’s Action Takes Aim At US Retirees
Trump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and global powers like China, Russia, and even Europe rapidly moving away from the U.S. dollar, central banks and financial giants are frantically buying gold at historic rates. This massive shift threatens your retirement savings with inflation and market instability—potentially worse than 2008. But you can protect yourself today by leveraging a little-known IRS loophole that lets you diversify your IRA or 401(k) into gold—tax-free and penalty-free.
Venus Concept reports Q4 EPS ($11.23) vs ($20.14) last year
See More Venus Concept Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Venus Concept? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Venus Concept and other key companies, straight to your email.

About Venus Concept

Venus Concept (NASDAQ:VERO), a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.

View Venus Concept Profile

More Earnings Resources from MarketBeat